NCT01373177

Brief Summary

The objective of this randomized study is to test the hypothesis that scores on the Bayley Scales of Infant Development-III (Bayley-III) are higher than scores on the Bayley Scales of Infant Development-II (BSID-II) in the same group of infants who were born very preterm.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
119

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2011

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2011

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

June 13, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 14, 2011

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2015

Completed
Last Updated

November 21, 2019

Status Verified

November 1, 2019

Enrollment Period

4.1 years

First QC Date

June 13, 2011

Last Update Submit

November 19, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • The primary outcome is the mean difference between BSID-II Mental Development Index (MDI) and Bayley-III Cognitive Score.

    18-22 months

Secondary Outcomes (3)

  • Mean difference between BSID-II Physical Development Index and Bayley-III Composite Motor Score.

    18-22 months

  • Proportion of infants classified as having "developmental delay" (MDI <70 on BSID-II or either Language or Cognitive Score <70 on the Bayley-III).

    18-22 months

  • The mean difference in scores between time point one and time point two (a measure of learning or training).

    18-22 months

Study Arms (2)

BSID-II, then Bayley-III

ACTIVE COMPARATOR

Receive BSID-II testing 4-8 weeks before Bayley-III testing

Diagnostic Test: Bayley Scales of Infant Development-IIDiagnostic Test: Bayley Scales of Infant Development-III

Bayley-III, then BSID-II

ACTIVE COMPARATOR

Receive Bayley-III testing 4-8 weeks before BSID-II testing

Diagnostic Test: Bayley Scales of Infant Development-IIDiagnostic Test: Bayley Scales of Infant Development-III

Interventions

Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-II was published in 1993. BSID-II provides normative data from two scales - Mental Development Index (MDI), and Psychomotor Development Index (PDI).

Also known as: BSID-II
BSID-II, then Bayley-IIIBayley-III, then BSID-II

Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-III was released in 2006. BSID-III provides normative data from five scales - Cognitive, Language, Motor, Social-Emotional, and Adaptive.

Also known as: Bayley-III, BSID-III
BSID-II, then Bayley-IIIBayley-III, then BSID-II

Eligibility Criteria

Age18 Months - 22 Months
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Birth weight \<2000 grams and \<32 weeks
  • Corrected age of 18-22 months.

You may not qualify if:

  • English is not the primary language in the child's home.
  • Parent is unable to give informed consent for research participation.
  • Parent is unable to commit to returning for follow-up testing in 4-8 weeks.
  • Infant has severe medical illness or disability expected to impact his/her ability to participate in testing (ex: blindness, deafness, severe cerebral palsy, autism, tracheostomy).
  • Participation in a RCT that restricts timing and administration of developmental testing.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States

Location

Study Officials

  • Sara B. DeMauro, MD

    Children's Hospital of Philadelphia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 13, 2011

First Posted

June 14, 2011

Study Start

January 1, 2011

Primary Completion

February 1, 2015

Study Completion

February 1, 2015

Last Updated

November 21, 2019

Record last verified: 2019-11

Locations